Could This Be Pfizer’s Biggest Week At The US FDA For COVID Products?

With an EUA submission for its Paxlovid treatment pill and expected authorization for universal adult vaccine boosters, Pfizer is establishing a portfolio of COVID products that could be used well after the eventual lifting of the public health emergency.

Paxlovid
Pfizer seeks FDA emergerency use authorization of its COVID-19 pill • Source: Alamy

Less than two weeks after announcing interim results of a Phase II/III study of its COVID-19 oral antiviral Paxlovid, Pfizer Inc. filed an application for emergency use authorization with the US Food and Drug Administration on 16 November.

CEO Albert Bourla noted that the filing was coming earlier in the day. Speaking at the Stat Summit, he said...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet